Development and commercialization of pharmaceuticals with novel mechanisms of action
First written in FY2023-Q3. 8 of 9 entries say "Restated". Latest entry: FY2027-H1.
The whole theme swung hardest in 2019: 1 of 10 companies on the "Worse" side.
4 other companies' latest entry also says "Restated".
- FY2027-H1RestatedAnnual report
「As in the previous fiscal year, the Company continued to pursue steady pipeline development and pipeline expansion through both internal and external sources.」
There has been no material change to the core policy of developing and launching proprietary drugs based on novel mechanisms, and the Company continues to develop and expand multiple pipeline programs. - FY2025RestatedAnnual report
「The Company’s objective is to develop drug candidates based on novel mechanisms of action and deliver breakthrough drugs to patients that address unmet medical needs.」
The Company continues to pursue its objective of developing candidates based on novel mechanisms of action and delivering drugs that address unmet medical needs. - FY2025-H1RestatedAnnual report
「The Company’s clinical pipeline increased from 1 to 3 programs in the previous fiscal year. During the interim accounting period (1 March 2024 to 31 August 2024), continued development progress and further expansion through internal and external sources resulted in the addition of 1 new preclinical program.」
The Company continues to prioritize clinical pipeline development and expansion through internal and external sources. - FY2025-Q1RestatedAnnual report
「The Company’s clinical pipeline increased from 1 to 3 programs in the previous fiscal year. During the first quarter of the current fiscal year, the Company worked to steadily advance development and further expand the pipeline through both internal and external sources.」
The Company is advancing and expanding its clinical pipeline through internal and external sources, with no material change to its established direction of developing and launching proprietary drugs. - FY2024-Q3RestatedAnnual report
「Against this backdrop, during the first nine months of the fiscal year, the Company pursued its business activities as described below, with the aim of developing and launching proprietary drugs based on mechanisms unlike any previously seen.」
The Company continues to pursue its core objective of developing and launching proprietary drugs based on novel mechanisms. - FY2024-Q2RestatedAnnual report
「Against this backdrop, during the first six months of the fiscal year, the Company pursued its business activities as described below, with the aim of developing and launching proprietary drugs based on mechanisms unlike any previously seen.」
The Company continues to pursue its core objective of developing and launching proprietary drugs based on novel mechanisms. - FY2024-Q1RestatedAnnual report
「Against this backdrop, during the first quarter of the fiscal year, the Company pursued its business activities as described below, with the aim of developing and launching proprietary drugs based on mechanisms unlike any previously seen.」
The Company continues to pursue its core objective of developing and launching proprietary drugs based on novel mechanisms. - FY2023RestatedAnnual report
「The Company’s objective is to develop drug candidates based on novel mechanisms of action and deliver breakthrough drugs to patients that address unmet medical needs.」
The Company reaffirmed its policy of developing drug candidates based on novel mechanisms of action, addressing unmet medical needs and pursuing commercialization. - FY2023-Q3First statedAnnual report
「The Company actively pursued its business activities with the aim of developing and launching proprietary drugs based on mechanisms unlike any previously seen.」
The Company has identified the development and launch of proprietary drugs based on novel mechanisms as a core objective.